Clinical trials: BPH (Benign Prostatic Hyperplasia)
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
- Trial name
- NCT00759135
- Testing
- 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
- Where
- 30 sites in United States
- Volunteers
- 85 people
- Sponsor
- Nymox Corporation
Benign Prostatic Hyperplasia (BPH), Overactive Bladder
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.
- Trial name
- NCT04485585
- Testing
- BR9006-1, BR9006-2
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Benign Prostatic Hyperplasia
Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia
The purpose of this study is to assess the safety and effectiveness of S-equol in men with benign prostatic hyperplasia.
- Trial name
- NCT00962390
- Testing
- S-equol
- Where
- 15 sites in United States, India
- Volunteers
- 116 people
- Sponsor
- Ausio Pharmaceuticals, LLC
Benign Prostatic Hyperplasia
Study to Compare the Safety and Pharmacokinetics of CKD-397
The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397 in healthy male volunteers.
- Trial name
- CKD-397 (NCT02645890)
- Testing
- CKD-397, TD+TM
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Erectile Dysfunction, Benign Prostatic Hyperplasia
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
The purpose of this study is to evaluate the efficacy, dose-response and safety of udenafil 25 mg, 50 mg and 75 mg every day (q.d.) for 12 weeks in the treatment of lower urinary tract symptoms (LUTS) associated with benign…
- Trial name
- NCT01967251
- Testing
- Udenafil
- Where
- 8 sites in Mexico
- Sponsor
- Takeda
Benign Prostatic Hyperplasia
AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia
Single-arm prospective, interventional clinical trial. Results will be compared to a historical control in the treatment of benign prostatic hyperplasia
- Trial name
- ABS (NCT03167294)
- Testing
- AquaBeam System
- Where
- India
- Volunteers
- 47 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia
Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)
This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).
- Trial name
- STRONG (NCT01259531)
- Testing
- Silodosin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction
- Trial name
- NCT02667938
- Testing
- HCP1303 capsule 5/0.2mg, HCP1303 capsule 5/0.4mg, HGP1201
- Volunteers
- 510 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hyperplasia
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.
- Trial name
- NCT01203371
- Testing
- Naftopidil, Tamsulosin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Benign Prostatic Hyperplasia
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.
Prostate adenoma or benign prostatic hypertrophy (BPH) is a benign disease of the prostate gland. It results in an increase in the volume of the prostate area located in contact with the urethra.
- Trial name
- NCT04853914
- Testing
- HIFU treatment
- Where
- France
- Volunteers
- 9 people
- Sponsor
- EDAP TMS S.A.
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Prostatic Hyperplasia
Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)
The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).
- Trial name
- NCT02245503
- Testing
- Tamsulosin
- Volunteers
- 7,391 people
- Sponsor
- Boehringer Ingelheim
Benign Prostate Hyperplasia
A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects
This is open-Label, A Randomized, Crossover study to evaluate the safety and pharmacokinetic interaction after oral concomitant administration of Dutasteride and Tadalafil in healthy male volunteers.
- Trial name
- NCT02839122
- Testing
- Tadalafil, Dutasteride
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yuyu Pharma, Inc.
Benign Prostatic Hyperplasia
Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia
The study objective is to evaluate the safety and feasibility of the Vivifi device to treat symptomatic, benign prostatic hyperplasia (BPH).
- Trial name
- BPH (NCT07745621)
- Testing
- Minimally invasive percutaneous ablation
- Where
- Panama
- Volunteers
- 20 people
- Sponsor
- Vivifi Medical
Prostatic Hyperplasia
ALF-ONE : ALFuzosin ONcE Daily
The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms…
- Trial name
- NCT00280605
- Testing
- Alfuzosin
- Volunteers
- 200 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia (BPH)
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)
The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment…
- Trial name
- NCT01775488
- Testing
- Vortx Rx - Histotripsy BPH Device
- Sponsor
- HistoSonics, Inc.
Benign Prostatic Hyperplasia
A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers
The study compare and evaluate the bioequivalence between the administration of AD-116A and the administration of AD-1161 in healthy adult male volunteers
- Trial name
- NCT07715305
- Testing
- AD-116A, AD-1161
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Prostatic Hyperplasia
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate.
- Trial name
- NCT00457457
- Testing
- Tamsulosin, UK-369,003
- Where
- 46 sites in Australia, Belgium and 13 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Male Infertility, Benign Prostatic Hyperplasia
The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility
Spermotrend is a natural based product manufactured by Catalysis Laboratories. Its composition contains different essential elements for spermatogenesis: selenium, zinc and fructose.
- Conditions
- Male Infertility, Benign Prostatic Hyperplasia, Spermatogenesis and Semen Disorders
- Trial name
- NCT05222841
- Testing
- Spermotrend
- Where
- Nicaragua
- Volunteers
- 150 people
- Sponsor
- Catalysis SL